Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6045469 | 1.00 | KCNN4 (0.32) | KCNN4MDM2KIF11ALDH1A1ALOX15 | |
| SCHEMBL7051771 | 0.83 | ALDH1A1 (0.44) | KCNN4MDM2ALDH1A1ALOX15 | |
| SCHEMBL7051372 | 0.83 | ALDH1A1 (0.44) | KCNN4MDM2ALDH1A1ALOX15 | |
| SCHEMBL7050025 | 0.83 | ALDH1A1 (0.44) | KCNN4MDM2ALDH1A1ALOX15 | |
| SCHEMBL7051369 | 0.83 | ALDH1A1 (0.44) | KCNN4MDM2ALDH1A1ALOX15 | |
| SCHEMBL7051770 | 0.83 | ALDH1A1 (0.44) | KCNN4MDM2ALDH1A1ALOX15 | |
| SCHEMBL6045509 | 0.79 | KIF11 (0.32) | KIF11 | |
| SCHEMBL6045475 | 0.79 | KIF11 (0.32) | KIF11 | |
| SCHEMBL10579044 | 0.71 | KIF11 (0.40) | KIF11ALOX15 | |
| SCHEMBL9496419 | 0.71 | KIF11 (0.40) | KIF11ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252774-A1 | Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases | NEW JERSEY, UNIVERSITY OF MEDICINE AND DENTISTRY OF | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252774-A1 | Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases | ADCY5, ADCY6, ADCY2 | KCNN4 1688/4885MDM2 4666/4885KIF11 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.